Galapagos NV (NASDAQ:GLPG) Given Consensus Recommendation of “Hold” by Analysts

Shares of Galapagos NV (NASDAQ:GLPG) have been given an average rating of “Hold” by the seven ratings firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $36.50.

GLPG has been the topic of several research reports. Royal Bank Of Canada upped their price target on Galapagos from $32.00 to $33.00 and gave the company a “sector perform” rating in a report on Tuesday, February 24th. Weiss Ratings raised Galapagos from a “sell (d)” rating to a “hold (c)” rating in a research note on Thursday, February 26th. Raymond James Financial restated a “market perform” rating on shares of Galapagos in a report on Tuesday, February 24th. UBS Group reaffirmed a “market perform” rating on shares of Galapagos in a research report on Tuesday, February 24th. Finally, Wall Street Zen raised Galapagos from a “hold” rating to a “buy” rating in a report on Saturday, March 28th.

Galapagos Stock Performance

Shares of GLPG opened at $28.00 on Friday. Galapagos has a one year low of $24.74 and a one year high of $37.78. The stock’s fifty day moving average is $30.81 and its 200-day moving average is $31.96. The firm has a market capitalization of $1.85 billion, a price-to-earnings ratio of -17.83 and a beta of 0.25.

Galapagos (NASDAQ:GLPG) last posted its quarterly earnings data on Sunday, February 15th. The biotechnology company reported $13.92 earnings per share (EPS) for the quarter. The company had revenue of $1.06 billion during the quarter. Analysts forecast that Galapagos will post -6.97 EPS for the current fiscal year.

Institutional Investors Weigh In On Galapagos

Hedge funds have recently bought and sold shares of the business. Quadrant Capital Group LLC purchased a new stake in Galapagos in the 3rd quarter worth approximately $134,000. Arax Advisory Partners grew its holdings in shares of Galapagos by 319.2% during the 4th quarter. Arax Advisory Partners now owns 2,335 shares of the biotechnology company’s stock valued at $76,000 after acquiring an additional 1,778 shares in the last quarter. Van ECK Associates Corp grew its holdings in shares of Galapagos by 61.6% during the 4th quarter. Van ECK Associates Corp now owns 1,968 shares of the biotechnology company’s stock valued at $64,000 after acquiring an additional 750 shares in the last quarter. State of Wyoming acquired a new position in shares of Galapagos in the second quarter worth $28,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in shares of Galapagos in the first quarter worth $248,000. 32.46% of the stock is owned by hedge funds and other institutional investors.

Galapagos Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.